ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

In brief: ring appointed Associate Dean At UCSF; Univ. of Utah Forms Cell Signaling Center

August 1, 1997

Three Venerable Acronyms Fade Away As Cooperative Groups Form “Alliance”

June 17, 2011

Cancer Act Renewal Nears Vote By House

August 11, 1978

NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation

June 12, 1992

Women 80 And Older Benefit From Mammography

May 30, 2008

NCI To End CIS Partnership Program In 2010.

December 5, 2008